<< Back to News

New formulation of IMBRUVICA®

Pharmacyclics LLC and Janssen Biotech, Inc., are pleased to share that they received US FDA approval for a new formulation of IMBRUVICA® as one pill, once a day. The same active ingredient is approved in one pill at multiple dosage strengths. No matter what dose a patient requires, they take just one pill a day. 

In addition, they recently received FDA approval for a new dosage strength of 70 mg for patients with moderate hepatic impairment or in patients with B-cell malignancies who are concomitantly taking specific posaconazole dosing regimens. Please refer to full IMBRUVICA® Prescribing Information for Dosing and Administration details.

Prescribing Information

NDC Flashcard